Systematic Financial Management LP bought a new stake in shares of Humana Inc. (NYSE:HUM - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 4,474 shares of the insurance provider's stock, valued at approximately $1,135,000.
Several other institutional investors and hedge funds also recently made changes to their positions in the business. Pinnacle Wealth Management Advisory Group LLC boosted its stake in shares of Humana by 3.6% during the 4th quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider's stock valued at $272,000 after buying an additional 37 shares during the last quarter. Mather Group LLC. boosted its stake in shares of Humana by 21.0% during the 4th quarter. Mather Group LLC. now owns 236 shares of the insurance provider's stock valued at $60,000 after buying an additional 41 shares during the last quarter. Capital Advisors Ltd. LLC boosted its stake in shares of Humana by 26.1% during the 4th quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider's stock valued at $53,000 after buying an additional 43 shares during the last quarter. Retirement Planning Co of New England Inc. boosted its stake in shares of Humana by 4.7% during the 4th quarter. Retirement Planning Co of New England Inc. now owns 966 shares of the insurance provider's stock valued at $245,000 after buying an additional 43 shares during the last quarter. Finally, LFA Lugano Financial Advisors SA lifted its stake in Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after purchasing an additional 45 shares during the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the company. JPMorgan Chase & Co. reduced their price objective on Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 18th. StockNews.com upgraded Humana from a "hold" rating to a "buy" rating in a research note on Friday, May 9th. Morgan Stanley reduced their price objective on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 12th. Barclays raised their price objective on Humana from $270.00 to $322.00 and gave the stock an "equal weight" rating in a research note on Friday, April 11th. Finally, Guggenheim initiated coverage on Humana in a research note on Wednesday, April 9th. They issued a "buy" rating and a $326.00 target price on the stock. Seventeen investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, Humana currently has an average rating of "Hold" and a consensus price target of $286.81.
Get Our Latest Stock Analysis on Humana
Humana Price Performance
NYSE:HUM traded up $7.89 during mid-day trading on Tuesday, reaching $255.23. 1,878,205 shares of the stock were exchanged, compared to its average volume of 1,770,415. The business has a fifty day moving average price of $262.98 and a 200 day moving average price of $269.38. The firm has a market capitalization of $30.80 billion, a PE ratio of 25.65, a PEG ratio of 2.05 and a beta of 0.49. Humana Inc. has a 1-year low of $212.45 and a 1-year high of $406.46. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68.
Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, beating analysts' consensus estimates of $10.07 by $1.51. Humana had a return on equity of 11.70% and a net margin of 1.02%. The business had revenue of $32.11 billion for the quarter, compared to the consensus estimate of $32 billion. During the same quarter in the previous year, the company posted $7.23 earnings per share. Humana's revenue for the quarter was up 8.4% compared to the same quarter last year. Research analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.
Humana Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 annualized dividend and a dividend yield of 1.39%. Humana's payout ratio is 25.04%.
About Humana
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Recommended Stories
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
